Creative Enzymes, a global enzyme technology service provider, recently launched an AI-integrated platform that takes a systematic approach to accelerating enzyme catalyst development. By merging computational enzyme engineering with hands-on process development know-how, the platform delivers AI-Driven Biocatalysis Solutions that are predictable in silico and practical at industrial scale.
While biocatalysis is an established manufacturing process, a significant gap remains between identifying application opportunities and having suitable enzymes available. Traditional development approaches are ill-equipped to meet the speed requirements of iterative product development. AI brings critical value on three fronts: predicting enzyme candidates best suited for a given reaction; designing enzymes constrained by process parameters rather than biological factors; and leveraging key molecular features to anticipate process performance in advance.
The benefits of a biocatalyst-based approach extend beyond speed. AI techniques reduce the need to experiment with myriad biocatalyst variants, saving on R&D costs. They also reduce the risk of process failure by identifying suitable biocatalysts earlier in development, while opening routes to molecules previously inaccessible to enzymatic conversion. This creates new product opportunities and allows for development of new biocatalytic processes.
The platform's capabilities are delivered through three specialized service modules. The AI-Driven Industrial Biocatalysis module addresses the journey from reaction engineering to full-scale implementation—encompassing substrate concentration optimization, cofactor regeneration, product inhibition management, immobilization, formulation development, integration of process analytical technology, and delivery of complete technology transfer packages including SOPs and regulatory documentation. The AI-Driven Green Biocatalysis module provides sustainability-focused solutions that align with corporate environmental goals, as enzymatic reactions typically occur in aqueous media at room temperature, minimizing organic solvent use and emissions while reducing byproduct formation and waste generation.
For moderately complex targets, the platform reduces the design-build-test-learn cycle from 12–24 months to just 8–12 months. Its end-to-end workflow spans target reaction analysis, computational screening, process optimization across key parameters (temperature, pH, solvent, substrate loading, cofactor availability), and scale-up evaluation covering expression yield and operational half-life. Quantitative data is passed from each stage to the next, ensuring development decisions are driven by empirical evidence.
The platform's capabilities have been demonstrated through a recent AI-driven case study in transaminase engineering. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations with precision. Five transaminase variants selected by AI—each with nine mutations—exhibited high solubility and catalytic stability at 7-liter fermentation scale. The engineered enzymes convert prochiral ketones to sitagliptin, delivering enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up production.
Pharmaceutical applications are where AI biocatalysis is making the biggest impact—asymmetric synthesis of chiral intermediates and replacing hazardous reagents with cleaner routes are already underway. Agrochemicals and food industries are following, with the former fine-tuning toxicology profiles and the latter delivering cleaner labels through enzymatic modification. Fine chemicals and personal care are beginning to explore high-value conversions and milder, more sustainable processes.
